Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Thyroid and Metabolic Disease Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for DIO1 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | DIO1 Recombinant Protein (ER Luminal Catalytic Domain) High purity (>95%), Endotoxin <1EU/µg. Sequence Verified. HEK293 Expressed. |
View DIO1 Products |
| Gene Delivery | DIO1 Lentivirus Premade Particles Full-length ORF with SECIS element for selenocysteine incorporation. High Titer (>10^8 TU/mL). |
View DIO1 Products |
| Benchmark Ab | Anti-DIO1 (Research Grade, Sequence Verified) Rabbit recombinant monoclonal for Western/IP detection. |
View DIO1 Products |
| Validator | DIO1 siRNA Set (3 unique sequences) For knockdown verification in HepG2 cells. Endotoxin controlled. |
View DIO1 Products |
| Related Target: DIO2 | Type II Deiodinase Selectivity counter-screen (avoid CNS hypothyroidism risk). |
View DIO2 Products |
| Related Target: DIO3 | Type III Deiodinase Ortholog for mechanism comparison (inactivating enzyme). |
View DIO3 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Selenocysteine (Sec) incorporation fidelity | Codon-optimized ORF with native SECIS element; Mass spec verified theoretical MW |
| Isoform Selectivity (DIO1 vs DIO2/DIO3) | Ortholog panel available: Human/Mouse/Cyno DIO1, DIO2, DIO3 proteins (>95% purity) |
| ER Membrane Topology preservation | Lentivirus-stable HepG2 cell lines preserving endogenous ER environment |
| Species Cross-reactivity (Tox studies) | Human, Cynomolgus, Rat DIO1 proteins sequence aligned for epitope conservation |
Live DIO1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for DIO1 (Type I iodothyronine deiodinase) therapeutics is intensifying, with major players shifting focus from pan-deiodinase inhibitors (e.g., PTU) to liver-selective DIO1-specific small molecules. As first-generation inhibitors enter Phase I for thyrotoxicosis and hepatocellular carcinoma (HCC), the next wave of R&D is targeting Non-Alcoholic Steatohepatitis (NASH) through hepatic metabolic reprogramming. Classical inhibitors like propylthiouracil (PTU) have defined the baseline, but the next wave is targeting highly selective small molecules and gene therapies for localized metabolic disorders, NASH, and specific oncology indications.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitors | Vitalio (BridgeBio), Academic Consortia | Thyrotoxicosis, HCC, NAFLD | Enzymatic conversion assay (T4→T3), Selectivity panel vs DIO2/DIO3 |
| Allosteric Modulators | Discovery Stage | Metabolic Syndrome | SECIS-dependent expression assay (Lentivirus-based) |
| siRNA / Gene Therapy | Preclinical | Rare Thyroid Disorders | Knockdown validation with DIO1-specific siRNA |
Molecular Differentiation & Assay Strategy
Best-in-class drug development for DIO1 must overcome the following differentiation hurdles:
- Isoform Selectivity (DIO1 vs DIO2/DIO3): The catalytic domains of DIO1, DIO2, and DIO3 share high homology, but DIO2 has a unique N-terminal domain. Cross-inhibition can lead to CNS hypothyroidism and TSH dysregulation. Assay Strategy: Establish a full deiodinase panel (DIO1, DIO2, DIO3) for biochemical and cell-based selectivity screening.
- Selenocysteine (Sec) Sensitivity: DIO1 activity depends on a selenocysteine-containing active site. Assays must distinguish direct enzyme inhibition from selenocofactor depletion.
- ER Membrane Topology: DIO1 is a type II transmembrane protein with its catalytic domain in the ER lumen. Drugs must penetrate the cell membrane and ER lumen, or use ER-targeted PROTACs.
- Species Cross-reactivity: For preclinical tox studies, drugs must show consistent inhibition kinetics across rodent and non-human primate DIO1 orthologs. Assay Strategy: Include Mouse/Cyno DIO1 proteins or cell lines for parallel IC50 determination.
TarMart Solution: Given the challenges of purifying active full-length DIO1 with selenocysteine, TarMart strongly recommends using Lentivirus Premade Particles to generate stable cell lines (HEK293 or HepG2) overexpressing DIO1, DIO2, and DIO3. Cell-based T4-to-T3 conversion assays preserve native membrane topology and post-translational modifications, providing the most physiologically relevant readout for drug selectivity and penetration.